Karoly Nikolich

CEO, Alkahest, Inc.; Venture Partner, Pivotal bioVentures; Adjunct Professor, Stanford University Medical School

Karoly Nikolich led Genentech’s entry into neuroscience during the 1980s and led and participated in the development of numerous protein therapeutics. He was Vice President of Research at Lynx Therapeutics, co-founder of AGY Therapeutics, Amnestix, Neurofluidics, Chase Pharmaceuticals, Circuit Therapeutics, and Alkahest. Karoly is a Venture Partner with Pivotal BioVentures, a life science focused investment fund. Karoly has served on the boards and scientific advisory boards at a number of neurotherapeutics and biotech companies, investment funds, as well as foundations. Karoly is a graduate of Eotvos University in Budapest and worked as a postdoctoral fellow at Tulane University and UCSF before joining Genentech. He has been Adjunct Professor in the Department of Psychiatry at Stanford University Medical School.